Latest Administration News

BlinkLab Limited has secured independent scientific validation for its smartphone-based autism diagnostic technology through publication in the prestigious journal Autism Research, marking a significant milestone ahead of its FDA regulatory trial.

Island Pharmaceuticals reports ongoing FDA review of its antiviral Galidesivir, with no adverse feedback received as the regulator takes extra time to finalise guidance.

Neurizon Therapeutics has progressed its ALS treatment NUZ-001 into critical clinical trial phases, even as the FDA declines its Fast Track Designation request pending more data.

Alara Resources' joint venture in Oman is under legal scrutiny as local residents seek to halt operations and challenge project licences. The company disputes the claims and continues production while monitoring developments.

Ainsworth Game Technology has issued a Target's Statement responding to an unsolicited proportional takeover bid by Kjerulf David Hastings Ainsworth amid an ongoing full takeover offer from Novomatic. The Independent Board Committee refrains from recommending acceptance or rejection, highlighting complex shareholder choices.

Memphasys Limited has extended the repayment terms of its convertible notes with major shareholder Peters Investments to mid-2026, reinforcing financial flexibility amid ongoing commercial progress.

Arovella Therapeutics has taken a significant step forward by submitting an IND application to the U.S. FDA for its lead CAR-iNKT cell therapy, ALA-101, targeting blood cancers. This milestone paves the way for a first-in-human Phase 1 trial in both Australia and the U.S.

Sprintex Limited has landed its largest-ever €15.6 million order for ZLD-UP® manure processing systems, marking a pivotal shift from evaluation to commercial deployment across Europe. This multi-year contract sets the stage for substantial revenue growth and a path to profitability in FY26.

Memphasys has secured CE Mark approval for its Felix™ sperm selection system, enabling full commercial rollout across Europe and activating multi-year contracts worth over A$1.3 million. This milestone signals the company’s transition into a revenue-scaling phase with global growth ambitions.

Dimerix secures FDA confirmation that proteinuria reduction is a valid primary endpoint for its Phase 3 ACTION3 trial, advancing its kidney disease drug DMX-200 closer to approval.

The FDA’s recent ruling classifying traditionally prepared kava beverages as food under U.S. law clears a major regulatory hurdle for The Calmer Co, accelerating its growth on Amazon and strengthening its U.S. expansion strategy.

Next Science Limited has applied for voluntary delisting from the ASX following the sale of nearly all its assets to OSARTIS GmbH. The company proposes a capital return to shareholders and intends to commence winding up after delisting.